These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 30595680)
21. UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions. Zheng N; Christopher LJ; Ma X; Ji QC; Buzescu A; Kandoussi H; Garonzik SM; LaCreta F; Aubry AF; Arnold ME; Zeng J Bioanalysis; 2016 Dec; 8(23):2429-2443. PubMed ID: 27855510 [TBL] [Abstract][Full Text] [Related]
22. Midazolam and cortisol metabolism before and after CYP3A induction in humans. Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773 [TBL] [Abstract][Full Text] [Related]
23. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. Ohno M; Yamaguchi I; Ito T; Saiki K; Yamamoto I; Azuma J Eur J Clin Pharmacol; 2000; 55(11-12):861-5. PubMed ID: 10805065 [TBL] [Abstract][Full Text] [Related]
24. Plasma 6β-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method. Hirano R; Yokokawa A; Furihata T; Shibasaki H Br J Clin Pharmacol; 2024 Apr; 90(4):1016-1026. PubMed ID: 38102865 [TBL] [Abstract][Full Text] [Related]
25. Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry. Oda A; Suzuki Y; Sato B; Sato H; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K J Sep Sci; 2022 May; 45(10):1672-1682. PubMed ID: 35247297 [TBL] [Abstract][Full Text] [Related]
26. No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. Mannheimer B; Wagner H; Östenson CG; Diczfalusy U PLoS One; 2015; 10(4):e0121984. PubMed ID: 25835492 [TBL] [Abstract][Full Text] [Related]
27. The utility of endogenous glycochenodeoxycholate-3-sulfate and 4β-hydroxycholesterol to evaluate the hepatic disposition of atorvastatin in rats. Ma Y; Xin M; Wen Y; Wang H; Zhang G; Dai J; Wu XA Asian J Pharm Sci; 2021 Jul; 16(4):519-529. PubMed ID: 34703500 [TBL] [Abstract][Full Text] [Related]
28. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Atoh K; Itoh H; Haneda M Diabetes Res Clin Pract; 2009 Feb; 83(2):220-6. PubMed ID: 19027976 [TBL] [Abstract][Full Text] [Related]
29. Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction. Totsuka S; Watanabe T; Koyanagi F; Tanaka K; Yasuda M; Manabe S Arch Toxicol; 1999; 73(4-5):203-7. PubMed ID: 10463384 [TBL] [Abstract][Full Text] [Related]
30. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393 [TBL] [Abstract][Full Text] [Related]
31. Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes. Gravel S; Chiasson JL; Gaudette F; Turgeon J; Michaud V Clin Pharmacol Ther; 2019 Oct; 106(4):831-840. PubMed ID: 31002385 [TBL] [Abstract][Full Text] [Related]
32. Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol. Bergström H; Lindahl A; Warnqvist A; Diczfalusy U; Ekström L; Björkhem-Bergman L Pharmacol Res Perspect; 2021 Dec; 9(6):e00884. PubMed ID: 34664787 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Shin KH; Choi MH; Lim KS; Yu KS; Jang IJ; Cho JY Clin Pharmacol Ther; 2013 Nov; 94(5):601-9. PubMed ID: 23784264 [TBL] [Abstract][Full Text] [Related]
34. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys. Tahara H; Watanabe M; Hasegawa M Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384 [TBL] [Abstract][Full Text] [Related]
35. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Taki K; Tsuruta Y; Niwa T Am J Nephrol; 2007; 27(1):30-5. PubMed ID: 17215572 [TBL] [Abstract][Full Text] [Related]
36. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Ushiama H; Echizen H; Nachi S; Ohnishi A Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002 [TBL] [Abstract][Full Text] [Related]
37. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation. Penzak SR; Rojas-Fernandez C J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026 [TBL] [Abstract][Full Text] [Related]
38. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471 [TBL] [Abstract][Full Text] [Related]
39. The ratio of 6β-hydroxycortisol to cortisol in urine as a measure of cytochrome P450 3A activity in postmortem cases. Lang LM; Linnet K J Forensic Sci; 2014 Jul; 59(4):1036-40. PubMed ID: 24611975 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of 6β-Hydroxycortisol and 6β-Hydroxycortisone as Biomarkers for Cytochrome P450 3A Activity: Insight into Their Predictive Value for Estimating Oral Immunosuppressant Metabolism. Luo X; Zheng L; Cai N; Liu Q; Yang S; He X; Cheng Z J Pharm Sci; 2015 Oct; 104(10):3578-86. PubMed ID: 26150050 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]